Anebulo Pharmaceuticals, Inc. (ANEB)
↓ Download CSVKey ratios (FY2025)
-72.8%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Income | -$9.22M | -$8.31M | -$11.78M | -$6.83M | -$3.61M | — |
| Net Income | -$8.48M | -$8.20M | -$11.73M | -$6.83M | -$30.25M | — |
| EPS (Diluted) | $-0.25 | $-0.32 | $-0.47 | $0.29 | $-2.83 | — |
| Total Assets | $12.15M | $4.07M | $11.67M | $15.58M | $21.65M | $3.03M |
| Total Liabilities | $487.7K | $260.6K | $1.07M | $512.5K | $241.6K | $223.9K |
| Shareholders' Equity | $11.66M | $3.81M | $10.60M | $15.07M | $21.41M | -$171.1K |
| Cash & Equivalents | $11.63M | $3.09M | $11.25M | — | — | — |
| Operating Cash Flow | -$6.35M | -$8.09M | -$9.68M | -$5.44M | -$4.87M | — |
| Shares Outstanding | 41.08M | 25.93M | 25.63M | 23.34M | 23.34M | 12.00M |